Liposomal nanosystems in rheumatoid arthritis

Margarida Ferreira-Silva, Catarina Faria-Silva, Pedro Viana Baptista, Eduarda Fernandes, Alexandra Ramos Fernandes, Maria Luísa Corvo

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease that affects the joints and results in reduced patient quality of life due to its chronic nature and several comorbidities. RA is also associated with a high socioeconomic burden. Currently, several available therapies minimize symptoms and prevent disease progression. However, more effective treatments are needed due to current therapies’ severe side-effects, especially under long-term use. Drug delivery systems have demonstrated their clinical importance—with several nanocarriers present in the market—due to their capacity to improve therapeutic drug index, for instance, by enabling passive or active targeting. The first to achieve market authorization were liposomes that still represent a considerable part of approved delivery systems. In this manuscript, we review the role of liposomes in RA treatment, address preclinical studies and clinical trials, and discuss factors that could hamper a successful clinical translation. We also suggest some alterations that could potentially improve their progression to the market.

Original languageEnglish
Article number454
JournalPharmaceutics
Volume13
Issue number4
DOIs
Publication statusPublished - Apr 2021

Keywords

  • Active targeting
  • Drug delivery nanosystems
  • Liposomes
  • Passive targeting
  • Rheumatoid arthritis

Fingerprint

Dive into the research topics of 'Liposomal nanosystems in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this